ArticleJournal of immunology (Baltimore, Md. : 1950)2010
GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- HIV-1 drug resistance among HIV/HCV co-infected patients with treatment failure in Yunnan, southwestern China: a cross-sectional study.Frontiers in microbiology · 2026Article
- The relationship between HERVs and exogenous viral infections: A focus on the value of HERVs in disease prediction and treatment.Virulence · 2025Review
- Characterization of Serotype-Specific Dengue Virus T-Cell Inhibition.The Journal of infectious diseases · 2025Article
- Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.Virulence · 2022Review
- Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.Virology journal · 2022Review
- Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?Frontiers in immunology · 2022Review
- Inactivation of Severe Acute Respiratory Coronavirus Virus 2 (SARS-CoV-2) and Diverse RNA and DNA Viruses on Three-Dimensionally Printed Surgical Mask Materials.Infection control and hospital epidemiology · 2021Article
- A Caulobacter crescentus Microbicide Protects from Vaginal Infection with HIV-1Journal of virology · 2019Article
- Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.Journal of virology · 2018Article
- Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.The Journal of infectious diseases · 2017Article
- GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1.Oncotarget · 2015Article
- Conserved Motifs within Hepatitis C Virus Envelope (E2) RNA and Protein Independently Inhibit T Cell Activation.PLoS pathogens · 2015Article
- GBV-C infection and risk of NHL among U.S. adults.Cancer research · 2014Article
- Cutting edge: An antibody recognizing ancestral endogenous virus glycoproteins mediates antibody-dependent cellular cytotoxicity on HIV-1-infected cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Bayesian analysis and classification of two enzyme-linked immunosorbent assay tests without a gold standard.Statistics in medicine · 2013Article
- GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- GB virus type C E2 protein inhibits human immunodeficiency virus type 1 assembly through interference with HIV-1 gag plasma membrane targeting.The Journal of infectious diseases · 2013Article
- Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.The Journal of general virology · 2013Article
- GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.Virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Broadly neutralizing Abs to HIV-1 are well described; however, identification of Ags that elicit these Abs has proven difficult. Persistent infection with GB virus type C (GBV-C) is associated with prolonged survival in HIV-1-infected individuals, and among those without HIV-1 viremia, the presence of Ab to GBV-C glycoprotein E2 is also associated with survival. GBV-C E2 protein inhibits HIV-1 entry, and an antigenic peptide within E2 interferes with gp41-induced membrane perturbations in vitro, suggesting the possibility of structural mimicry between GBV-C E2 protein and HIV-1 particles. Naturally occurring human and experimentally induced GBV-C E2 Abs were examined for their ability to neutralize infectious HIV-1 particles and HIV-1-enveloped pseudovirus particles. All GBV-C E2 Abs neutralized diverse isolates of HIV-1 with the exception of rabbit anti-peptide Abs raised against a synthetic GBV-C E2 peptide. Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2 Abs immune-precipitated HIV-1 gag particles containing the vesicular stomatitis virus type G envelope, HIV-1 envelope, GBV-C envelope, or no viral envelope. The Abs did not neutralize or immune-precipitate mumps or yellow fever viruses. Rabbit GBV-C E2 Abs inhibited HIV attachment to cells but did not inhibit entry following attachment. Taken together, these data indicate that the GBV-C E2 protein has a structural motif that elicits Abs that cross-react with a cellular Ag present on retrovirus particles, independent of HIV-1 envelope glycoproteins. The data provide evidence that a heterologous viral protein can induce HIV-1-neutralizing Abs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.